Vaccine Informatics
The Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA), established under the Japan Agency for Medical Research and Development (AMED) based on the "Government Strategy to Strengthen Vaccine Development and Production to Enable Rapid Approval," has launched a project to establish world-leading R&D centers for vaccine development in Japan. Nagasaki University applied to be one of the centers with three main topics: "Response to tropical infectious diseases," "Vaccine development against advanced BSL-4 pathogens," and "Vaccine development using artificial intelligence (AI)," and was selected as one of the vaccine R&D centers.
Members
- Professor
- Trevor Clancy
- Assistant
- Eriko Hashimoto
Activities
The development of infectious disease vaccines using AI is a new initiative for the university, and this new area of research has been established in collaboration with NEC OncoImmunity AS (NOI), a Norwegian company, and NEC headquarters. Professor Trevor Clancy, co-founder and Chief Science Officer of NOI, will lead this research area through a cross-appointment between NOI and Nagasaki University, and will direct and oversee the research and development. In addition, an international call for applications has been issued for a full-time associate professor, and a cross-appointment of an assistant professor from the NEC European Institute is also planned, which will promote the development of vaccines with an international flavor and advanced AI. The goal is to develop this field as a center for research on vaccines for infectious diseases using AI not only in Japan but also in the world, attracting human resources from around the world and enabling it to function as a center that contributes to the 100-day mission of vaccine development.